PCSK9 inhibition to lower LDL-cholesterol and reduce cardiovascular risk: Great expectations

Circulation Research

Volumn 116, Issue 10, 2015, Pages 1643-1645

  Waters, David D ^a   Hsue, Priscilla Y ^b  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; ANACETRAPIB; C REACTIVE PROTEIN; CERIVASTATIN; EVACETRAPIB; EVOLOCUMAB; LAROPIPRANT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; RIMONABANT; SERINE PROTEINASE; TORCETRAPIB; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HUMAN; INJECTION SITE REACTION; LIPID METABOLISM; META ANALYSIS (TOPIC); MUSCLE DISEASE; MYALGIA; NONSENSE MUTATION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW (TOPIC);

EID: 84942866753     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.306493     Document Type: Review

References (13)

1. Abifadel M, Varret M, Rabès JP, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34: 154-156. doi: 10.1038/ng1161
2. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koran MJ, Stein EA, Open-Label Study of Long-Term Evaluation Against LDL Cholesterol (OSLER) Investigators Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; March 15. Epub ahead of print
3. Robinson JG, Farnier M, Krempf M, ODYSSEY LONG TERM Investigators Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; March 15. epub ahead of print
4. Cholesterol Treatment Trialists' Collaboration Baigent C, Blackwell L, Emberson J, Cholesterol Treatment Trialists' Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010 376 1670 1681
5. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005 366 1267 1278
6. Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, Blom D, Eriksson M, Dent R, Wasserman SM, Huang F, Xue A, Albizem M, Scott R, Stein EA., Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol 2014; 63: 1278-1288. doi: 10.1016/j.jacc.2014.01.006
7. Boekholdt SM, Hovingh GK, Mora S, Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol 2014; 64: 485-494. doi: 10.1016/j.jacc.2014.02.615
8. FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm, Accessed March 23, 2015
9. Richardson K, Schoen M, French B, Umscheid CA, Mitchell MD, Arnold SE, Heidenreich PA, Rader DJ, deGoma EM., Statins and cognitive function: a systematic review. Ann Intern Med 2013; 159: 688-697. doi: 10.7326/0003-4819-159-10-201311190-00007
10. Hooper AJ, Burnett JR, Watts GF., Contemporary aspects of the biology and therapeutic regulation of the microsomal triglyceride transfer protein. Circ Res 2015; 116: 193-205. doi: 10.1161/CIRCRESAHA.116.304637
11. Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR., The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 2007; 193: 445-448. doi: 10.1016/j.atherosclerosis.2006.08.039
12. Rached FH, Chapman MJ, Kontush A., An overview of the new frontiers in the treatment of atherogenic dyslipidemias. Clin Pharmacol Ther 2014; 96: 57-63. doi: 10.1038/clpt.2014.85
13. http://www.goodreads.com/work/quotes/2612809-great-expectations, Accessed March 24, 2015